IP Library Patent Application 16063812
Patent Application
App. No. 16/063,812

MODULAR TRANSDERMAL DELIVERY SYSTEM AND ASSOCIATED METHODS OF MANUFACTURE AND USE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/063,812
Abstract

A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.

Claims (39)

1 . A modular transdermal delivery system for pre-use assembly and drug loading, wherein the system comprises:

an upper module comprising an outer backing layer, a pressure-sensitive adhesive layer laminated thereto, and a first removable release liner covering the pressure-sensitive adhesive layer; and

a lower module comprising a porous drug reservoir layer for adhering to the pressure-sensitive adhesive layer of the upper module upon assembly and into which the drug to be delivered will be loaded, and a skin-contact adhesive affixed to the drug reservoir layer,

wherein the system is free of a pharmacologically active agent.

2 . (canceled)

3 . The system of claim 1 , wherein the porous drug reservoir layer comprises a microporous polymeric matrix.

4 - 5 . (canceled)

6 . The system of claim 1 , wherein the skin-contact adhesive comprises a skin-contact adhesive layer that is laminated to the drug reservoir layer and serves as the basal surface of the system which adheres to a body surface during use.

7 . The system of claim 6 , further including a second removable release liner adhered to the skin-contact adhesive layer and thereby covering the basal surface of the system prior to use.

8 . (canceled)

9 . The system of claim 1 , wherein the pressure-sensitive adhesive layer contains a permeation enhancer.

10 - 11 . (canceled)

12 . The system of claim 1 , wherein the basal surface of the system has an area in the range of about 5 cm 2 to about 100 cm 2 .

13 . (canceled)

14 . The system of claim 1 , wherein the first removal release liner is scored or perforated to facilitate removal of the liner in at least two segments, sequentially.

15 . The system of claim 1 , wherein the skin-contact adhesive comprises a peripheral ring underlying the drug reservoir layer.

16 . The system of claim 6 , wherein the lower module further includes a release rate-controlling membrane between the porous drug reservoir layer and the skin contact adhesive layer.

17 . A modular transdermal delivery system for pre-use assembly, wherein the system comprises:

an upper module comprising an outer backing layer, a pressure-sensitive adhesive layer laminated thereto, and a first removable release liner covering the pressure-sensitive adhesive layer; and

a lower module comprising a porous drug reservoir layer for adhering to the pressure-sensitive adhesive layer of the upper module upon assembly, a skin-contact adhesive affixed to the drug reservoir layer, and, contained within the porous drug reservoir layer, a pharmaceutical formulation containing a pharmacologically active agent or a precursor thereto.

18 . (canceled)

19 . The system of claim 17 , wherein the porous drug reservoir layer comprises a microporous polymeric matrix.

20 - 21 . (canceled)

22 . The system of claim 17 , wherein the skin-contact adhesive comprises a skin-contact adhesive layer that is laminated to the drug reservoir layer and serves as the basal surface of the system which adheres to a body surface during use.

23 . The system of claim 22 , further including a second removable release liner adhered to the skin-contact adhesive layer and thereby covering the basal surface of the system prior to use, wherein the second removable release liner is optionally scored or perforated.

24 . The system of claim 22 , wherein the skin contact adhesive layer is comprised of a material selected to be permeable to the pharmaceutical formulation.

25 . The system of claim 17 , wherein the pressure-sensitive adhesive layer contains a permeation enhancer.

26 . The system of claim 17 , wherein the pharmaceutical formulation comprises a pharmacologically active agent.

27 . The system of claim 17 , wherein the pharmaceutical formulation comprises a precursor to a pharmacologically active agent.

28 . The system of claim 27 , wherein the pressure-sensitive adhesive layer contains an activator compound for converting the precursor to the pharmacologically active agent.

29 . The system of claim 26 , wherein the pressure-sensitive adhesive layer comprises a composition that exhibits low partitioning for the pharmacologically active agent.

30 . The system of claim 17 , wherein the basal surface of the system has an area in the range of about 5 cm 2 to about 100 cm 2 .

31 . (canceled)

32 . The system of claim 17 , wherein the first removal release liner is scored or perforated to facilitate removal of the liner in at least two segments, sequentially.

33 . The system of claim 17 , wherein the skin-contact adhesive comprises a peripheral ring underlying the drug reservoir layer.

34 . The system of claim 17 , wherein the lower module further includes a release rate-controlling membrane between the porous drug reservoir layer and the skin contact adhesive layer.

35 - 71 . (canceled)

72 . The system of claim 1 , wherein the porous drug reservoir layer has a porosity gradient such that porosity gradually decreases from an uppermost region of the reservoir layer to a lowermost region of the reservoir layer.

73 . The system of claim 17 , wherein the porous drug reservoir layer has a porosity gradient such that porosity gradually decreases from an uppermost region of the reservoir layer to a lowermost region of the reservoir layer.

Assignments (1)
SECURITY INTEREST Recorded Aug 3, 2022
From: PURE RATIOS HOLDING INC.
To: LI LENDING, LLC
Reel/Frame 060711/0712 →